TOCILIZUMAB
tocilizumab 400 mg/20 mL injection, 20 mL vial
TOCILIZUMAB (1482B)
1482B
Manner of administration:Injection
Restriction
Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)
Restriction
Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (retrial or recommencement of treatment after a break
of less than 12 months)
Restriction
Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break of more than
12 months)
Restriction
Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial
or recommencement of treatment after a break of less than 12 months) or Initial 3
(recommencement of treatment after a break of more than 12 months)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $399.39 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Actemra | |||||